Company intelligence / Profile preview

Vivtex

Cambridge, Massachusetts, United Statesvivtex.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Vivtex has demonstrated in published studies that its GI‑ORIS™ platform can accurately model intestinal absorption of drugs ex vivo. The company has entered multiple research collaborations with leading pharma/biotech companies to co-develop orally available versions of biologic drugs previously limited to injection or infusion. No clinical trial results have been reported as the company remains pre-clinical.

Therapeutic areas: OtherImmunology
Modalities: Oral biologicssmall moleculesminiproteins
Industry: Drug Discovery Services

Partnerships

Astellas Pharma Inc.AI ProteinsMultiple undisclosed leading pharma/biotech companies leveraging the GI‑ORIS™ platform for oral drug development

Beyond the preview

Go deeper on Vivtex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivtex.